Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.
Sophie A. Kurk(Utrecht University), Anne M. May(Utrecht University), Frans Erdkamp, Cornelis J.A. Punt(Utrecht University), Miriam Koopman(Utrecht University), Rebecca K. Stellato(University Medical Center Utrecht), P. Kint(Amphia Ziekenhuis), Lieke H. J. Simkens(Academic Medical Center), Manuel L. R. Tjin‐A‐Ton(Ziekenhuis Rivierenland), Petra H.M. Peeters(University Medical Center Utrecht), Bea C. Tanis(Leiden University Medical Center), Marion Jourdan(Nutricia Research (Netherlands)), Felix E. de Jongh, Ankie Van Der Velden(Tergooi), Sandra A. Radema(Radboud University Nijmegen), Bram Dorresteijn(Nutricia Research (Netherlands)), Geert‐Jan Creemers, Boelo Jan Poppema(Dialyse Centrum Groningen)
Cited by 6
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k